Group sales increasing by more than a fifth to €462.9m ($507m), as demand soared following the coronavirus outbreak, combined with a handle on costs led [Krka] to report earnings before interest and tax that were 85% higher at €133.9m in the first three months of this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?